Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
•
Infectious Disease
•
Immunosuppression
•
MRSA
What is your approach to a patient on immunosuppressants with an outpatient cutaneous MRSA infection or to a MRSA carrier?
Related Questions
How do you approach endocarditis prophylaxis for patients with rheumatic diseases undergoing invasive dental surgery and no history of joint replacement?
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
What is your approach to working up diarrhea in an immunocompromised patient?
What is your approach to RSV vaccination in immunocompromised patients?
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
What is the optimal timing for Zoster vaccine administration for a patient who recently recovered from herpes zoster infection and is now planning to start B-cell depletion therapy?
What is your approach to tapering chronic steroids in patients who are at high risk of HPA suppression?
Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?
